-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Underweight on XPLR Infr, Lowers Price Target to $10

Benzinga·12/02/2025 18:08:05
Listen to the news
Morgan Stanley analyst Robert Kad maintains XPLR Infr (NYSE:XIFR) with a Underweight and lowers the price target from $11 to $10.